Journal of Ovarian Research

Journal of Ovarian Research is a fully open-access, peer-reviewed journal published by BMC, part of Springer Nature, since 2008, devoted to ovarian biology in health and disease across the lifespan, with a 2025 Journal Impact Factor of 5.3.《卵巢研究杂志》（Journal of Ovarian Research）是（BMC）于 2008 年创办的全开放获取同行评审期刊，隶属（Springer Nature），聚焦女性一生中卵巢生物学与卵巢疾病的基础、转化与临床研究，2025 年影响因子为 5.3。

Scope

• Ovarian development, folliculogenesis and the hormonal regulation of ovarian function卵巢发育、卵泡发生与卵巢功能的激素调控。
• Ovarian ageing and premature ovarian insufficiency卵巢衰老与早发性卵巢功能不全。
• Infertility, polycystic ovary syndrome and diminished ovarian reserve不孕症、多囊卵巢综合征与卵巢储备功能下降。
• Ovarian and fallopian tube cancer, including precursor lesions and chemoresistance卵巢癌与输卵管癌，包括前驱病变与化疗耐药。
• Benign ovarian conditions and the molecular mechanisms of ovarian disease卵巢良性病变与卵巢疾病的分子机制。
• Drug discovery, drug repurposing and targeted therapies for ovarian dysfunction卵巢功能障碍的药物发现、老药新用与靶向治疗。
• Omics, biomarkers, artificial intelligence, stem cells, organoids and research on health disparities组学、生物标志物、人工智能、干细胞、类器官与健康差异研究。

History

• The journal was launched by BioMed Central in 2008, and its first volume appeared in October 2008该刊由（BioMed Central）于 2008 年创办，第 1 卷第 1 期于 2008 年 10 月上线。
• It has been fully open access since launch, with articles under CC BY or CC BY-NC-ND licences and an article processing charge of EUR 2990 or USD 3490自创刊起即为全开放获取，论文以（CC BY）或（CC BY-NC-ND）许可发表，版面费为 2990 欧元或 3490 美元。
• Publication is continuous, with one volume a year, and volume 17 appeared in 2024该刊实行连续出版，每年一卷，2024 年出至第 17 卷。
• BioMed Central is now part of Springer Nature, and the journal site has moved to the Springer Nature Link platform（BioMed Central）现已并入（Springer Nature），期刊网站亦迁至（Springer Nature Link）平台。
• It is indexed in Science Citation Index Expanded, MEDLINE, PubMed Central, Scopus, DOAJ and Embase该刊被（Science Citation Index Expanded）、（MEDLINE）、（PubMed Central）、（Scopus）、（DOAJ）与（Embase）收录。
• Its Journal Impact Factor moved from 4.234 in 2021 and 5.506 in 2022 to 4.2 in 2024 and 5.3 in 2025, ranking sixth among 44 journals in reproductive biology其影响因子由 2021 年的 4.234、2022 年的 5.506 变为 2024 年的 4.2 与 2025 年的 5.3，在生殖生物学领域 44 种期刊中位列第 6。

Editors

• The editors-in-chief are Adam R Karpf of the University of Nebraska Medical Center in Omaha, United States, who works on ovarian cancer, FOXM1, DNA methylation and epigenetic therapeutics, and Benjamin K Tsang of the University of Ottawa in Canada, who works on ovarian cancer and reproduction现任主编为（University of Nebraska Medical Center）的 Adam R Karpf 与（University of Ottawa）的 Benjamin K Tsang，前者研究卵巢癌、FOXM1、DNA 甲基化与表观遗传治疗，后者研究卵巢癌与生殖。
• Senior editors are Mei-Jou Chen of National Taiwan University, Makoto Orisaka of the University of Fukui, Ofer Reizes of the Cleveland Clinic, Rajesh Singh of the Morehouse School of Medicine and William Yeung of the University of Hong Kong高级编辑包括（National Taiwan University）的 Mei-Jou Chen、（University of Fukui）的 Makoto Orisaka、（Cleveland Clinic）的 Ofer Reizes、（Morehouse School of Medicine）的 Rajesh Singh 与（University of Hong Kong）的 William Yeung。
• Their fields run from reproductive endocrinology and folliculogenesis to ovarian cancer biology, the microbiome and assisted reproduction, and associate editors add expertise in cancer cell signalling and extracellular vesicles其专长从生殖内分泌、卵泡发生延伸到卵巢癌生物学、微生物组与辅助生殖，副编辑则补充了癌细胞信号转导与细胞外囊泡等方向。
• Editors and board members are drawn from the United States, Canada, Taiwan, Japan, Israel, Hong Kong and India, reflecting the journal's international authorship编辑与编委来自美国、加拿大、台湾、日本、以色列、香港与印度，与刊物的国际作者群相匹配。
• Peer review is single anonymous, with reviewers' names withheld from authors, and the median time from submission to first decision is 11 days该刊实行单盲评审，审稿人姓名对作者保密，投稿至首次决定的中位时间为 11 天。
• The journal publishes original research, reviews and thematic collections, and its author guidelines now require uncropped gel and blot images and stricter reporting for Mendelian randomization studies该刊刊载原创研究、综述与专题合集，作者指南现已要求提交未经裁剪的凝胶与印迹原图，并对孟德尔随机化研究提出更严格的报告要求。